LYEL Earnings

Quarterly EPS
$-3.48
Q3 2024
$-5.01
Q4 2024
$-3.54
Q1 2025
$-2.89
Q2 2025
$-2.13
Q3 2025
$-6.85
Q4 2025
$-1.10
Q1 2026
$-1.92
Q2 2026
Latest Revenue4.0K
Latest Net Income-44755000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$1.924.0K-44755000-50.0%+33.6%
Q1 2026-$1.102.0K-24153000-71.4%+68.9%
Q4 2025-$6.856.0K-140723000-45.5%-36.7%
Q3 2025-$2.1315.0K-38846000-55.9%+38.8%
Q2 2025-$2.898.0K-42684000-38.5%+19.5%
Q1 2025-$3.547.0K-52195000+133.3%+26.2%
Q4 2024-$5.0111.0K-191935000-15.4%-19.6%
Q3 2024-$3.4834.0K-44583000+36.0%+13.0%
Q2 2024-$3.5913.0K-45809000
Q1 2024-$4.803.0K-60667000
Q4 2023-$4.1913.0K-52930000
Q3 2023-$4.0025.0K-50853000
Lyell Immunopharma (LYEL) — Earnings